Janux Therapeutics (JANX) Receivables - Net (2020 - 2026)

Janux Therapeutics (JANX) has reported Receivables - Net for 6 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net changed N/A year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $35.0 million (changed N/A YoY), while the FY2020 annual figure was $8.0 million, changed N/A from the prior year.
• Receivables - Net rose to $35.0 million in Q1 2026 per JANX's latest filing, from $7.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $35.0 million in Q1 2026 and bottomed at $500000.0 in Q3 2022.
• Historically, Receivables - Net has averaged $8.8 million across 4 years, with a median of $750000.0 in 2023.
• On a YoY basis, Receivables - Net climbed as much as 33.33% in 2024 and fell as far as 33.33% in 2024.
• Janux Therapeutics' Receivables - Net stood at $500000.0 in 2022, then jumped by 50.0% to $750000.0 in 2023, then surged by 900.0% to $7.5 million in 2024, then jumped by 366.67% to $35.0 million in 2026.
• Business Quant data shows JANX's Receivables - Net at $35.0 million in Q1 2026, $7.5 million in Q2 2024, and $500000.0 in Q1 2024.